Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Olivier Laureau

Olivier Laureau

President of Servier Group

Appears in 1 story

Notable Quotes

"This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology. It reflects our long-term commitment to investing in science that can make a meaningful difference for patients." — Statement on Day One acquisition, March 2026

Stories

Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment

Money Moves

Leading Servier's 2030 oncology expansion strategy

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the Food and Drug Administration (FDA) cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Now the company behind it, Day One Biopharmaceuticals, has agreed to be acquired by France's Servier for $2.5 billion in cash, a 68% premium over its previous closing share price.

Updated Mar 6